OverviewThe global NLP in healthcare and life sciences market is witnessing rapid expansion and is expected to grow at an ...

Likozam® will be reimbursed to patients starting June 12, 2026 Official reimbursement ends the “Early Access” clawbackThe ...

Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with ...

"One DEA Schedule I laboratory registration approved. FDA INDs granted. Orphan Drug Designation awarded. Yet the cultivation application remains unresolved as patients continue to wait. This is ...

Camzyos has the potential to be the first pharmacological therapy for the treatment of oHCM in adolescents, addressing a high unmet need for this populationApplication based on positive results of ...

Pesticides. Mycotoxins. Fraudulent Lab Reports. Forged Certificates of Analysis. This Is the State-Licensed Cannabis and Hemp Supply Chain the Courts and DEA Just Handed a Federal Registration Pathway ...

A leading alcohol‑reduction specialist credits advances in moderation therapies for a decline in the number of UK ...

SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to ...

UPPSALA, SE / ACCESS Newswire / May 27, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB today announced that its TetraGraph® neuromuscular monitoring system has received an additional FDA Class II ...

The global hemodynamic monitoring systems market is projected to witness steady growth during the forecast period, expanding ...

OverviewThe global urology surgical instruments market is set to experience steady growth, with an anticipated compound ...

UPPSALA, SE / ACCESS Newswire / June 1, 2026 / Senzime AB (STO:SEZI)(OTCQX:SNZZF) today announced the launch of its latest ...